Merriman Curhan Ford Initiates Coverage on Pharmacyclics (PCYC) with a Buy; New Management, New Capital, New Pipeline
Tweet Send to a Friend
Merriman Curhan Ford initiates coverage on Pharmacyclics, Inc. (Nasdaq: PCYC) with a Buy rating. Price target range $5.50-7.50.
Merriman analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Merriman analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
